IPO got tremendous response
Reputed pharmaceutical company of Gujarat Senores Pharma It is going to be listed in the stock market on 30 December 2023. Open between 20th and 24th December Initial Public Offering (IPO) received an excellent response from investors. It received a total subscription of 93.41 times, which indicates that investors are deeply interested in this company.
Senores Pharma raised approx. from its IPO. Rs 582 crore The target has been set to collect. as well as, Rs 260.6 crore An amount of Rs. has already been raised from anchor investors.
Strong performance in gray market
Senores Pharma shares Grey Market In Premium of Rs 230 But doing business. this its issue price from about 58.8% more Is. Considering this performance, it is expected that its listing in the stock market may be at the level of Rs 621 per share.
What is gray market?
Gray market is an unofficial platform where buying and selling of shares takes place before listing in the stock market. However, market experts always recommend that investors take their decisions based on the financial position and performance of the company and not just on gray market signals.
Senores Pharma IPO: Key Details
- Price Band: Rs 372-391 per share
- Listing Date: 30 December 2023
- Stock Exchange: BSE and NSE
- Lot Size: 38 equity shares
- Minimum investment amount for retail investors: Rs 14,858
Learn about the company
Senores Pharma’s business is primarily focused on the regulated markets of the United States, Canada and the United Kingdom. Additionally, the company is also active in emerging markets in 43 other countries. This company is involved in critical care injectables and API (Active Pharmaceutical Ingredients) Produces.
Financial performance: strong figures
Senores Pharma has delivered impressive financial performance in recent years:
- March 2024:
- Net Profit: Rs 32.7 crore (4 times more than Rs 8.4 crore in the previous financial year)
- Revenue: Rs 214.5 crore (5 times increase from Rs 35.3 crore in FY 2023)
- September 2024 (6 months):
- Revenue: Rs 181 crore
- Benefit: Rs 23.94 crore
This impressive growth shows that the company is rapidly expanding its operations and continuously boosting profits.
Experts’ opinion on Senores Pharma IPO
This IPO may prove attractive for investors, especially considering the company’s strong financial performance and increasing global expansion. However, for long-term investment it is important to also keep an eye on the company’s strategy and its competition in the industry.
